iBio, Inc.
Close on Oct 19, 2026
- Market cap
- $110.48M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2026 Ended Jun 30, 2026 | Aug 28, 2026 | Before market open | – | – | – |
| Q3 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | – | – | – |
| Q2 FY2026 Ended Dec 31, 2025 | Feb 10, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | $100.00K | – | – |
| Q4 FY2025 Ended Jun 30, 2025 | Sep 5, 2025 | Before market open | – | – | – |
| Q3 FY2025 Ended Mar 31, 2025 | May 2, 2025 | Before market open | – | $-0.49 | – |
| Q2 FY2025 Ended Dec 31, 2024 | Feb 10, 2025 | After market close | $200.00K | $0.48 | – |
| Q1 FY2025 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | – | $-0.46 | – |
| Q4 FY2024 Ended Jun 30, 2024 | Sep 20, 2024 | After market close | – | – | – |
| Q3 FY2024 Ended Mar 31, 2024 | May 13, 2024 | After market close | – | $-0.71 | – |
| Q4 FY2023 Ended Jun 30, 2023 | Aug 7, 2023 | After market close | – | – | – |
Press releases
Announcements iBio filed with the SEC
iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CORPORATE PRESENTATION • September 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner,
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Certain statements in this presentation constitute "forward
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
SAN DIEGO, Jan. 9, 2026 (GLOBE NEWSWIRE) -- iBio,
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
SAN DIEGO, August 18, 2025 (GLOBE NEWSWIRE) --
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Pricing of $50 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Certain statements in this presentation constitute "forward
Results of operations · Other events · EX-99.1 to Form 8-K
meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
iBio Reports Fiscal Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Enabled by an AI-Platform Scalable
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
iBio to Begin Trading on the Nasdaq Stock Exchange
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
iBio Reports Fiscal Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
iBio Announces New Investments from Board Members and Officers
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Enabled by an AI-Platform Scalable
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
iBio Strengthens Board with Appointment of Two
Results of operations · Shareholder vote results · EX-99.1 to Form 8-K
iBio Reports Fiscal First Quarter 202 5 Financial Results
Results of operations · EX-99.1 to Form 8-K
amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend"
Regulation FD disclosure · EX-99.1 to Form 8-K
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
iBio Closes Sale of Manufacturing Facility in Texas
Agreement terminated · Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Agreement terminated · Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend"
Regulation FD disclosure · EX-99.1 to Form 8-K
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
iBio Announces $15.0 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend"
Regulation FD disclosure · EX-99.1 to Form 8-K
iBio Amends and Extends Maturity of Credit Agreement
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K